News Sentiment

ZYME sentiment intelligence

Zymeworks Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 25.88 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

74/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

-1.6% over one week, +13.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Zymeworks Inc. to Announce Second Quarter 2026 Financial Results on August 6, 2026

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 74/100 classification
One-week reaction -1.6% Price digesting
Trend fit Trend active 13.1% over four weeks
Fair value 79.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 29
Neutral 27
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 8
Barron's 3
simplywall.st 3
Quiver Quantitative 2
MarketBeat 2
Seeking Alpha 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Earnings 26
Market update 22
Deals and strategy 10
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
ICLG Direct company coverage

Arthur Cox advises on pharmaceutical sector acquisition

Irish law firm Arthur Cox advised Theravance Biopharma on its acquisition by biotechnology company Zymeworks Inc. The deal, valued at $929 million in equity, will see Theravance Biopharma shareholders receive cash and a contingent value right for future proceeds. This transaction

Tone
Positive 75/100
Event
Deals and strategy
Published
03 Jul 2026 21:40
Source
ICLG
The Globe and Mail Direct company coverage

Zymeworks offers US$929-million for COPD drug maker Theravance

Zymeworks Inc. is acquiring Dublin-based Theravance Biopharma Inc. for US$929-million in cash, financed partly by Zymeworks' own funds and partly by the Ontario Municipal Employees Retirement System (OMERS). This acquisition marks Zymeworks' entry into the respiratory illness mar

Tone
Neutral 50/100
Event
Deals and strategy
Published
30 Jun 2026 08:09
Source
The Globe and Mail
Business in Vancouver Direct company coverage

Vancouver biotech Zymeworks buying Theravance for US$929M

Vancouver-based Zymeworks Inc. is acquiring California's Theravance Biopharma Inc. for US$929 million in cash, a move that diversifies Zymeworks' drug portfolio beyond oncology into respiratory-disease treatments. This acquisition follows Theravance's disappointing clinical trial

Tone
Positive 63/100
Event
Deals and strategy
Published
29 Jun 2026 19:40
Source
Business in Vancouver
Moomoo Direct company coverage

Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery

Gandeeva Therapeutics and Zymeworks Inc. have announced a collaboration to use Gandeeva's cryo-electron microscopy (cryo-EM) platform to accelerate antibody drug discovery. This partnership aims to leverage cryo-EM technology to gain deeper structural insights into therapeutic an

Tone
Positive 71/100
Event
Deals and strategy
Published
20 Jun 2026 09:11
Source
Moomoo
Stock Titan Direct company coverage

Zymeworks partner maps a tiny antibody target at 2.6 Å

Gandeeva Therapeutics and Zymeworks have partnered to use cryo-electron microscopy (cryo-EM) to enhance antibody drug discovery. Their collaboration successfully resolved a nine-amino acid epitope of a small, flexible antigen bound to a Zymeworks antibody Fab at 2.6 Å resolution.

Tone
Positive 72/100
Event
Analyst action
Published
18 Jun 2026 11:39
Source
Stock Titan
Finviz Direct company coverage

ZYME - Zymeworks BC Inc Stock Price and Quote

This article provides a comprehensive overview of Zymeworks BC Inc. (ZYME) stock, including its latest closing price, financial metrics, analyst ratings, and recent news. It highlights the company's recent acquisition of Theravance Biopharma and details insider trading activity.

Tone
Positive 66/100
Event
Deals and strategy
Published
30 May 2026 20:09
Source
Finviz